Cat

This pack includes the recommended tests defined by the Flemish breeding program for Devon Rex: Congenital myasthenic syndrome (CAT-CMS) and Progressive retinal atrophy (CAT-PRA-RDAC).

This package includes the mandatory tests defined by the Flemish breeding program for Burmese: Frontonasal dysplasia (CAT-BHD), Hypokalemia (CAT-HK) and Gangliosidosis type 2 (CAT-GM2-BUR).

This package includes the mandatory tests defined by the Flemish breeding program for Bombay: Frontonasal dysplasia (CAT-BHD), Hypokalemia (CAT-HK) and Gangliosidosis type 2 (CAT-GM2-BUR).

This package includes the mandatory tests defined by the Flemish breeding program for Bengal: Pyruvate kinase deficiency (CAT-PKDEF) and Progressive retinal atrophy (CAT-PRA-BEN).

This pack includes the recommended tests defined by the Flemish breeding program forAngora Turc: Pyruvate kinase deficiency (CAT-PKDEF) and Drugs sensibility (CAT-MDR1).

This pack includes the recommended tests defined by the Flemish breeding program for l'Australian Mist: l'hypokaliémie (CAT-HK), Pyruvate kinase deficiency (CAT-PKDEF), Gangliosidosis type 2 (CAT-GM2-BUR) and Progressive retinal atrophy (CAT-PRA-RDAC).

This package includes the mandatory tests defined by the Flemish breeding program for Abyssin: Pyruvate kinase deficiency (CAT-PKDEF) and Progressive retinal atrophy (CAT-PRA-RDAC).

Progressive retinal atrophy (PRA) linked to the AIPL1 gene is a hereditary genetic disease described in Persian cats. It causes rapid degeneration of retinal photoreceptors, with the onset of cell loss as early as 5 weeks of age and severe involvement by 16 weeks. The first clinical signs include an early decrease in night vision, followed by loss of daytime vision.

GM1 gangliosidosis is a fatal genetic disease caused by a deficiency of the enzyme β-galactosidase. This enzyme normally helps break down certain complex lipids called gangliosides, particularly GM1 ganglioside. In the absence of this enzyme, these compounds progressively accumulate within cells, especially in nervous tissue. The disease generally manifests around the age of 3 months and reaches its terminal stage at around 9 to 10 months, with the onset of blindness and epileptiform seizures. Affected animals exhibit an unsteady gait, loss of coordination, tremors, and progressive muscle weakness, leading to severe neurological decline.

In domestic cats, the common blood groups are A and B; a third rare blood group, AB, is also known. This terminology is confusing because type AB is not the result of the presence of both blood groups A and B. A genetic mutation associated with blood group B in most cats has been identified. Genetic testing therefore makes it possible to determine whether a cat is bb (blood group B), Ab (carrier of the b allele with blood group A or AB), or AA (blood type A or AB). This test is particularly important in cats because of neonatal isoerythrolysis. Indeed, the colostrum of a mother with blood group B can kill a kitten if it belongs to blood group A or AB.

This test analyzes mutations specific to the Neva Masquerade breed and is not valid for other breeds.